NSCLC
Conditions
Interventions
Treatment group:None
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18–75 years, regardless of gender. 2. Patients with stage II–III non-small cell lung cancer (NSCLC) confirmed by histological or cytological examination, based on the 8th edition of the AJCC (American Joint Committee on Cancer) staging system. 3. Patients who have previously undergone curative lung cancer surgery. 4. Patients who have previously received =2 cycles of neoadjuvant platinum-based doublet chemotherapy combined with PD-1/PD-L1 antibody treatment. 5. EGFR or ALK wild-type status or unknown mutation status before neoadjuvant treatment.
Exclusion criteria
Exclusion criteria: 1. Patients with clinical stage I, unresectable stage III, or stage IV non-small cell lung cancer (NSCLC). 2. Patients with a history of other malignancies, or those who have other malignancies during neoadjuvant treatment (except for malignancies that have been completely resected and have not recurred for 5 years postoperatively, such as cervical carcinoma in situ, basal cell carcinoma of the skin, and papillary thyroid carcinoma). 3. Patients who have previously received other systemic anti-tumor treatments. 4. Patients who have received neoadjuvant targeted therapy ± chemotherapy. 5. Patients who have not undergone surgical treatment. 6. Patients with incomplete key clinical and treatment information are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate;Disease control rate;Radiological Downstaging Rate;R0 resection rate;Major Pathological Response Rate;Pathological Complete Response Rate;Pathological Downstaging Rate;Event-free survival;overall survival; | — |
Countries
China
Contacts
Public ContactJun Chen
Tianjin Medical University General Hospital
Outcome results
None listed